Thermo Fisher Scientific Recognized with Six CMO Leadership Awards
News provided by
Share this article
Share this article
WALTHAM, Mass., Feb. 18, 2021 /PRNewswire/ Thermo Fisher Scientific, the world leader in serving science, today announced it has won six awards in the annual CMO Leadership Awards. The awards, presented by
Life Science Leader and
Outsourced Pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies.
Thermo Fisher won across all six categories, including: Capabilities, Compatibility, Expertise, Quality, Reliability and Service. This is the second consecutive year Thermo Fisher has received this recognition across all six categories and eighth time overall that the company has been honored by the CMO Leadership Awards.
Vetter Pharma International GmbH: Vetter continues its successful performance at the 2021 CMO Leadership Awards
Vetter reaffirms its high performance in customer-critical aspects
Results reflect the positive experience of pharma and biotech companies in their daily work with the service provider particularly during a pandemic
Winning five awards mirrors the company s core value of customer partnership Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), was granted the 2021 CMO Leadership Awards in five core categories
quality,
capabilities, and
service. The award, now in its tenth year, was given by the leading trade press publication, Life Science Leader. Vetter was also the recipient of the award in a variety of categories in previous years.
Research Report Shows Phase II/III Spending Will Increase
By Ed Miseta, Chief Editor, Clinical Leader
Follow Me On Twitter @EdClinical
Research firm
Industry Standard Research recently published its Phase II/III Study Trends and Market Outlook report. The goal of this report is to provide readers with a high-level view of the Phase II/III clinical development space to illustrate current market dynamics and inform strategic planning. For this report, 146 Phase II/III decision-makers were surveyed to share their insights into where the Phase II/III market is now and what changes they expect over the next four years.
Research Report Shows Phase II/III Spending Will Increase
By Ed Miseta, Chief Editor, Clinical Leader
Follow Me On Twitter @EdClinical
Research firm
Industry Standard Research recently published its Phase II/III Study Trends and Market Outlook report. The goal of this report is to provide readers with a high-level view of the Phase II/III clinical development space to illustrate current market dynamics and inform strategic planning. For this report, 146 Phase II/III decision-makers were surveyed to share their insights into where the Phase II/III market is now and what changes they expect over the next four years.